But an association with improved overall survival failed to reach statistical significance ...

When PSA rises after surgery, PSMA PET/CT detects cancer missed by conventional imaging ...

The main market opportunities lie in the commercialization and development of PSMA-targeted therapies and radiodiagnostics for prostate cancer. Key areas include expansion in radioligand therapy and ...

Frontiers in Oncology publication positions metabo-oncology as a differentiated platform for pharma and a novel, ...

One in eight men will develop prostate cancer in their lifetime. Surgery to treat the disease can lead to unwelcome side effects. A minimally invasive alternative that avoids surgery is now available ...

Long-used imaging strategies such as computed tomography (CT) and bone scintigraphy (BS) to detect lymph node and bone metastases have significant limitations and disadvantages. Newly emerging ...

For the last three years, Bayer has been implementing a new strategy for its oncology development, a strategy that led to multiple approvals, as well as a number of promising new programmes added to ...

Read more in the PNW Health series. Prostate cancer is the second-most common cancer among men in the U.S., affecting 13 out of every 100 American men over the course of their lifetime. About two to ...

Study reveals geographic differences in the use of innovative technological approaches to diagnose and treat prostate cancer. The study looked at the effect of regional hospital competition and ...

Given the low mortality from slow-growing, localized prostate cancers and the side effects of many treatments, deciding whether to opt for monitoring or treatment can be excruciatingly difficult.